{"disease":{"id":"neoplasm-of-prostate","name":"Neoplasm of prostate","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"estramustine","indication_name":"Neoplasm of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estracty","generic_name":"ESTRAMUSTINE","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"Alkylating Drug","quality_score":null,"revenue":null,"mechanism":"Estramustine works by attaching an alkyl group to DNA, interfering with cell division and ultimately killing cancer cells."},{"drug_id":"flutamide","indication_name":"Neoplasm of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eulexin","generic_name":"flutamide","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":54,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06835218","title":"PROCARE - PROstate Cancer Real World Evidence Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UroTrials Company (GmbH)","has_results":false},{"nct_id":"NCT03181867","title":"18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":800,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04534075","title":"Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT00643617","title":"CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry","phase":"NA","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Accuray Incorporated","has_results":true},{"nct_id":"NCT06657131","title":"Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT06235099","title":"Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Curium US LLC","has_results":false},{"nct_id":"NCT06150417","title":"MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05022914","title":"PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE","phase":"","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria Careggi","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT07084779","title":"Investigation of Impact of AI on Prostate Cancer Workflow","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03939689","title":"I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Progenics Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05847348","title":"68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Telix Pharmaceuticals (Innovations) Pty Limited","has_results":false},{"nct_id":"NCT05252390","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT02499835","title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":true},{"nct_id":"NCT06957691","title":"Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Shehzad Basaria, M.D.","has_results":false},{"nct_id":"NCT02713269","title":"Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05407311","title":"64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Clarity Pharmaceuticals Ltd","has_results":true},{"nct_id":"NCT05249127","title":"64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Clarity Pharmaceuticals Ltd","has_results":true},{"nct_id":"NCT04931979","title":"SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":49,"lead_sponsor_name":"Prof. Dr. med. Christian Gratzke","has_results":false},{"nct_id":"NCT06574880","title":"STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Angela Y. Jia, MD PhD","has_results":false},{"nct_id":"NCT03475433","title":"An Observational Prospective Cohort Study Using an Actigraphy Device.","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Taipei Medical University","has_results":false},{"nct_id":"NCT01638533","title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02099864","title":"Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":true},{"nct_id":"NCT02632669","title":"Hemi-Ablative Prostate Brachytherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Royal Surrey County Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT06437496","title":"68Ga-AAZTA-093 PET/CT: First-in-human Study","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT03388619","title":"Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07118176","title":"Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05048537","title":"18F-FACBC PET/CT and the PSA Kinetics for PCa Patients With Biochemical Recurrence.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT02362464","title":"Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT05582031","title":"Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Translational Research in Oncology","has_results":false},{"nct_id":"NCT05238831","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04765423","title":"Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03035357","title":"Neoadjuvant Listeria or Daratumumab in Prostate Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":34},"guidelines":[],"source":"Drug Landscape verified database"}